Meet The Top Attys In AbbVie's Antitrust Battle Royal

Law360 (June 7, 2019, 8:00 PM EDT) -- Powerhouse plaintiffs lawyers and BigLaw brawlers are set for a rowdy antitrust battle over AbbVie’s alleged scheme to protect the market for its immunosuppressant Humira, the world’s best-selling drug, by cultivating an impenetrable “patent thicket” and engaging in devious horse-trading with biosimilar makers.  

In an order Tuesday, U.S. District Judge Manish S. Shah consolidated a dozen proposed class actions that are leveling potentially groundbreaking attacks on patenting practices and "pay-for-delay" deals in the pharmaceutical industry. In addition to AbbVie Inc., defendant drugmakers include Amgen Inc., Pfizer Inc., Sandoz Inc., Mylan Inc., Momenta Pharmaceuticals Inc., Samsung Bioepis Co. Ltd. and Fresenius Kabi USA LLC.

All of the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS